Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.
A pre-recorded presentation will be available on-demand starting Tuesday, October 11, 2022. Please visit https://meetingonthemesa.com for full information including registration.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Lisa Raffensperger
Ten Bridge Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(617) 903-8783
Investor Contact
Chris Brinzey
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
(339) 970-2843
| Last Trade: | US$2.72 |
| Daily Volume: | 0 |
| Market Cap: | US$116.440M |
October 04, 2023 February 16, 2023 November 10, 2022 | |
DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORE
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORE
